 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Feb 9, 2017
P1, N=65, Not yet recruiting, Sponsor: Children's Oncology Group
N=36 --> 65
- prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Feb 2, 2017
P1, N=12, Recruiting, Sponsor: Eli Lilly and Company
N=36 --> 65 Trial primary completion date: Jan 2018 --> Jun 2017
- prexasertib (ACR-368) / Acrivon Therap
Trial initiation date: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Jan 30, 2017
P1, N=36, Not yet recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2018 --> Jun 2017 Initiation date: Sep 2016 --> Feb 2017
- |||||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P3 trial: IGNITE3: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (clinicaltrials.gov) - Jan 26, 2017
P3, N=1200, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
- prexasertib (ACR-368) / Acrivon Therap
Enrollment change, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Jan 12, 2017
P2, N=144, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Sep 2016 --> Feb 2017 N=108 --> 144
- |||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment open: IGNITE4: Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - Jan 12, 2017
P3, N=400, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
N=108 --> 144 Not yet recruiting --> Recruiting
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Dec 9, 2016
P2, N=116, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2018 --> Dec 2017
- | tolcapone (CRX-1008) / Corino Therap, SOM Biotech
Trial completion, Trial primary completion date: Study of SOM0226 in Familial Amyloid Polyneuropathy (clinicaltrials.gov) - Nov 30, 2016
P1/2, N=17, Completed, Sponsor: SOM Biotech SL
Trial primary completion date: Aug 2018 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Nov 2015
- prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Metastases: A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (clinicaltrials.gov) - Oct 18, 2016
P2, N=38, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Metastases: A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer (clinicaltrials.gov) - Oct 7, 2016
P1, N=10, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | prexasertib (ACR-368) / Acrivon Therap
Phase classification, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 22, 2016
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Phase classification: P1 --> P1b
- ||| prexasertib (ACR-368) / Acrivon Therap, ralimetinib (LY 2228820) / Eli Lilly
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 12, 2016
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Aug 29, 2016
P1, N=12, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Jan 2018
- ||| prexasertib (ACR-368) / Acrivon Therap, ralimetinib (LY 2228820) / Eli Lilly
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Aug 9, 2016
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company
- | prexasertib (ACR-368) / Acrivon Therap
Phase classification, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Jul 23, 2016
P1b, N=70, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Aug 2017 --> Jan 2018 Phase classification: P1 --> P1b
- | prexasertib (ACR-368) / Acrivon Therap
New P1 trial: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Jun 22, 2016
P1, N=36, Not yet recruiting, Sponsor: Children's Oncology Group
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P3 trial: IGNITE4: Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - May 27, 2016
P3, N=0, Not yet recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
- |||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial primary completion date: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - May 25, 2016
P3, N=840, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Phase classification: P1 --> P1b Trial primary completion date: Feb 2016 --> Sep 2015
- prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Metastases: A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer (clinicaltrials.gov) - May 19, 2016
P1, N=10, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - May 18, 2016
P2, N=116, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Feb 2016 --> Sep 2015 Not yet recruiting --> Recruiting
- prexasertib (ACR-368) / Acrivon Therap
Enrollment open: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - May 6, 2016
P1, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| prexasertib (ACR-368) / Acrivon Therap
Trial completion, Metastases: A Phase 1 Study in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=150, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| prexasertib (ACR-368) / Acrivon Therap
New P2 trial: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Apr 13, 2016
P2, N=116, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion, Trial primary completion date: IGNITE1: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - Mar 21, 2016
P3, N=541, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Aug 2014
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Feb 26, 2016
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Aug 2014 Not yet recruiting --> Recruiting
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Metastases: A Phase 1 Study in Participants With Advanced Cancer (clinicaltrials.gov) - Feb 9, 2016
P1, N=150, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Apr 2016
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 11, 2016
P1, N=185, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2015 --> Apr 2016 N=115 --> 185
- | prexasertib (ACR-368) / Acrivon Therap
New P1 trial: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 7, 2016
P1, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment closed, Trial primary completion date: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Nov 24, 2015
P3, N=840, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
N=115 --> 185 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Feb 2016
- prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Oct 22, 2015
P1, N=12, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Oct 6, 2015
P1, N=12, Not yet recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Aug 2017
- prexasertib (ACR-368) / Acrivon Therap
Enrollment change, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Sep 25, 2015
P2, N=108, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Aug 2017 N=78 --> 108
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
N=78 --> 108 Trial primary completion date: Oct 2017 --> Apr 2018
- ||| prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Sep 21, 2015
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Metastases: A Phase 1 Study in Participants With Advanced Cancer (clinicaltrials.gov) - Aug 13, 2015
P1, N=150, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2017 --> Apr 2018 Trial primary completion date: Oct 2015 --> Jul 2015
- | prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Aug 3, 2015
P1, N=12, Not yet recruiting, Sponsor: Eli Lilly and Company
- prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Jul 13, 2015
P2, N=78, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Jul 2015 Trial primary completion date: Jun 2019 --> Jun 2018
- tolcapone (CRX-1008) / Corino Therap, SOM Biotech
Trial primary completion date: Study of SOM0226 in Familial Amyloid Polyneuropathy (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=20, Recruiting, Sponsor: SOM Biotech SL
Trial primary completion date: Jun 2019 --> Jun 2018 Trial primary completion date: Nov 2014 --> Jul 2015
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jun 11, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2014 --> Jul 2015 N=70 --> 115
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 14, 2015
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
N=70 --> 115 Trial primary completion date: Oct 2017 --> Jun 2016
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment closed, Metastases: A Phase 1 Study in Participants With Advanced Cancer (clinicaltrials.gov) - Dec 10, 2014
P1, N=150, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2017 --> Jun 2016 Recruiting --> Active, not recruiting
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Nov 12, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2017
- prexasertib (ACR-368) / Acrivon Therap
Enrollment open, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 21, 2014
P2, N=78, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2016 --> Oct 2017 Not yet recruiting --> Recruiting
- prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 4, 2014
P2, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Jun 2019
- ||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment closed: IGNITE1: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - Jul 23, 2014
P3, N=536, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Trial primary completion date: Jun 2018 --> Jun 2019 Recruiting --> Active, not recruiting
- tolcapone (CRX-1008) / Corino Therap, SOM Biotech
New P1/2 trial: Study of SOM0226 in Familial Amyloid Polyneuropathy (clinicaltrials.gov) - Jul 16, 2014
P1/2, N=20, Recruiting, Sponsor: SOM Biotech SL
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jul 1, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P1 trial: A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects (clinicaltrials.gov) - May 7, 2014
P1, N=12, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P1 trial: A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects (clinicaltrials.gov) - May 7, 2014
P1, N=24, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
- ||| prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 24, 2014
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company